BMS-986365
BMS-986365 is an experimental protein degrader from Celgene in phase 3 trials for prostate cancer, aimed at Androgen receptor.
Overview
BMS-986365 is a protein degrader developed by Celgene. Its target is Androgen receptor (the sponsor names androgen receptor (AR)). The sponsor states: A dual androgen receptor ligand-directed degrader and antagonist, i.e. it both degrades the AR protein and blocks its activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer), in prostate cancer. The largest, NCT06764485, plans to enrol 960 participants with primary completion expected 2027-09-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"BMS-986365" OR ABSTRACT:"BMS-986365") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BMS-986365, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAZD9750
Shares Androgen receptor, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentQLH12016
Shares Androgen receptor, Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentEP0062
Shares Androgen receptor and the tags pipeline, ctgov-ingest.
- TreatmentAtigotatug
Shares Bristol Myers Squibb and the tags pipeline, ctgov-ingest.
- TreatmentFPI-2265
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentAZD6621
Shares Prostate cancer and the tags pipeline, ctgov-ingest.
- TreatmentArlocabtagene Autoleucel
Shares Bristol Myers Squibb and the tags pipeline, ctgov-ingest.
- TreatmentXNW5004
Shares Prostate cancer and the tags pipeline, ctgov-ingest.